Selective JAK Inhibition in RA vs PV - Top-Institutions - MDSpire

Selective JAK Inhibition in RA vs PV

Tofacitinib induced remission of rheumatoid arthritis but spared JAK2-driven polycythemia vera in a single case report.

  • By

  • Julia Cipriano

  • February 13, 2026

  • 3 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Rheumatology
    • Hematology
    • Translational Medicine

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Rheumatology
    • Hematology
    • Immunology

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Rheumatology
    • Hematology
    • Molecular Medicine

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Rheumatology
    • Hematology
    • Clinical Pharmacology

Original Source(s)

Selective JAK Inhibition in RA vs PV

  • by Julia Cipriano

  • February 13, 2026

Related Content

Dry Eye Across Autoimmune Diseases

The nationwide analysis found the highest rates of dry eye disease among patients with Sjögren’s syndrome.

Oxidative Balance, Inflammation Linked to RA Mortality

Higher oxidative balance was associated with lower mortality, while greater systemic inflammation was linked to increased risk in a US cohort of patients with rheumatoid arthritis.

Botulinum Toxin Evaluated in Digital Ischemia

Individual-level meta-analysis examines response, dosing, and safety across ischemic etiologies